HRP20191291T1 - Imunogeni pripravak - Google Patents
Imunogeni pripravak Download PDFInfo
- Publication number
- HRP20191291T1 HRP20191291T1 HRP20191291TT HRP20191291T HRP20191291T1 HR P20191291 T1 HRP20191291 T1 HR P20191291T1 HR P20191291T T HRP20191291T T HR P20191291TT HR P20191291 T HRP20191291 T HR P20191291T HR P20191291 T1 HRP20191291 T1 HR P20191291T1
- Authority
- HR
- Croatia
- Prior art keywords
- fragment
- proximal end
- polypeptide according
- toxin
- repeat
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims 4
- 239000012634 fragment Substances 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 241000193163 Clostridioides difficile Species 0.000 claims 4
- 101710182223 Toxin B Proteins 0.000 claims 3
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 2
- 101710182532 Toxin a Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Claims (13)
1. Polipeptid koji sadrži prvi fragment i drugi fragment, naznačen time što
(i) prvi fragment je fragment ponavljajuće domene toksina A iz bakterije C. difficile;
(ii) drugi fragment je fragment ponavljajuće domene toksina B iz bakterije C. difficile;
(iii) prvi fragment ima prvi proksimalni kraj;
(iv) drugi fragment ima drugi proksimalni kraj; i
gdje je prvi proksimalni kraj unutar kratkog ponavljanja i drugi proksimalni kraj je unutar kratkog ponavljanja; i
gdje su prvi fragment i drugi fragment jedan uz drugog, te gdje polipeptid izaziva protutijela koja neutraliziraju toksin A i toksin B.
2. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što polipeptid izaziva zaštitni imunosni odgovor kod sisavačkog domaćina protiv sojeva bakterije C. difficile.
3. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što prvi fragment i/ili drugi fragment sadrže manje od 25%, 20%, 18% ili 15% strukture alfa-uzvojnice.
4. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi fragment i/ili drugi fragment sadrže više od 25%, 30%, 35%, 38% ili 40% strukture beta-nabrane ploče.
5. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi proksimalni kraj ne prekida dio s kratkim ponavljanjem-dugim ponavljanjem-kratkim ponavljanjem.
6. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što drugi proksimalni kraj ne prekida dio s kratkim ponavljanjem-dugim ponavljanjem-kratkim ponavljanjem.
7. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi proksimalni kraj i drugi proksimalni kraj ne prekidaju dijelove s kratkim ponavljanjem-dugim ponavljanjem-kratkim ponavljanjem.
8. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi proksimalni kraj nije među aminokiselinama 1878-1940, 2012-2074, 2146-2208, 2258-2322, 2394-2456, 2507-2569 ili 2598-2660 toksina A.
9. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što drugi proksimalni kraj nije među aminokiselinama 1881-1942, 2012-2074, 2144-2208 ili 2278-2339 toksina B.
10. Polinukleotid, naznačen time što kodira polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-9.
11. Imunogeni pripravak, naznačen time što sadrži polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-9, kao i farmaceutski prihvatljivu pomoćnu tvar.
12. Imunogeni pripravak u skladu s patentnim zahtjevom 11, naznačen time što dodatno sadrži adjuvans.
13. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 11-12, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti koju uzrokuje bakterija C. difficile.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490716P | 2011-05-27 | 2011-05-27 | |
| US201161490734P | 2011-05-27 | 2011-05-27 | |
| US201161490707P | 2011-05-27 | 2011-05-27 | |
| EP16193340.3A EP3138916B1 (en) | 2011-05-27 | 2012-05-25 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191291T1 true HRP20191291T1 (hr) | 2019-10-18 |
Family
ID=46168484
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231749TT HRP20231749T1 (hr) | 2011-05-27 | 2012-05-25 | Imunogeni pripravak |
| HRP20170094TT HRP20170094T1 (hr) | 2011-05-27 | 2017-01-20 | Imunogeni pripravak |
| HRP20180339TT HRP20180339T1 (hr) | 2011-05-27 | 2018-02-23 | Imunogeni pripravak |
| HRP20191291TT HRP20191291T1 (hr) | 2011-05-27 | 2019-07-17 | Imunogeni pripravak |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231749TT HRP20231749T1 (hr) | 2011-05-27 | 2012-05-25 | Imunogeni pripravak |
| HRP20170094TT HRP20170094T1 (hr) | 2011-05-27 | 2017-01-20 | Imunogeni pripravak |
| HRP20180339TT HRP20180339T1 (hr) | 2011-05-27 | 2018-02-23 | Imunogeni pripravak |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9409974B2 (hr) |
| EP (6) | EP4296361A3 (hr) |
| JP (3) | JP2014516532A (hr) |
| KR (1) | KR102014502B1 (hr) |
| CN (3) | CN103717742B (hr) |
| BR (2) | BR112013030395B1 (hr) |
| CA (2) | CA2837395C (hr) |
| CY (3) | CY1118599T1 (hr) |
| DK (4) | DK3138916T3 (hr) |
| EA (1) | EA030898B1 (hr) |
| ES (3) | ES2615737T3 (hr) |
| FI (1) | FI3564378T3 (hr) |
| HR (4) | HRP20231749T1 (hr) |
| HU (4) | HUE044772T2 (hr) |
| IL (1) | IL229529B2 (hr) |
| LT (4) | LT2714910T (hr) |
| ME (1) | ME02600B (hr) |
| MX (1) | MX346200B (hr) |
| PL (4) | PL3138916T3 (hr) |
| PT (4) | PT3138916T (hr) |
| RS (1) | RS55605B1 (hr) |
| SG (1) | SG195037A1 (hr) |
| SI (4) | SI2714911T1 (hr) |
| SM (1) | SMT201700110B (hr) |
| WO (3) | WO2012163810A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2753352T5 (pl) | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| BR122019017005B1 (pt) | 2011-04-22 | 2022-03-29 | Wyeth Llc | Composições que se relacionam a uma toxina de clostridium difficile mutante |
| SG11201402375VA (en) * | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| JP6290918B2 (ja) | 2012-12-05 | 2018-03-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| CN105451762A (zh) * | 2013-04-22 | 2016-03-30 | 俄克拉荷马州大学评议会 | 艰难梭菌疫苗及使用方法 |
| EP3271375B1 (en) | 2015-02-19 | 2021-02-24 | Immune Biosolutions Inc. | Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof |
| MX2020013623A (es) * | 2018-06-19 | 2021-03-25 | Glaxosmithkline Biologicals Sa | Composicion inmunogenica. |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| CN1176658A (zh) * | 1994-10-24 | 1998-03-18 | 蛇药制品有限公司 | 治疗和预防艰难梭菌疾病的疫苗和抗毒素 |
| JPH11509200A (ja) * | 1995-07-07 | 1999-08-17 | オラバックス インク． | 粘膜アジュバントとしてのクロストリジウム・ディフィシール（Ｃｌｏｓｔｒｉｄｉｕｍ Ｄｉｆｆｉｃｉｌｅ）トキシン |
| JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| AU781027B2 (en) | 1999-04-09 | 2005-04-28 | Department Of Health & Human Services | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines |
| WO2001073030A2 (en) | 2000-03-28 | 2001-10-04 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| US20120020996A1 (en) * | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
| US10046040B2 (en) * | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| PL2753352T5 (pl) | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
-
2012
- 2012-05-25 PL PL16193340T patent/PL3138916T3/pl unknown
- 2012-05-25 WO PCT/EP2012/059792 patent/WO2012163810A1/en active Application Filing
- 2012-05-25 CA CA2837395A patent/CA2837395C/en active Active
- 2012-05-25 DK DK16193340.3T patent/DK3138916T3/da active
- 2012-05-25 LT LTEP12724950.6T patent/LT2714910T/lt unknown
- 2012-05-25 SI SI201230868A patent/SI2714911T1/sl unknown
- 2012-05-25 SG SG2013085386A patent/SG195037A1/en unknown
- 2012-05-25 PL PL19179871.9T patent/PL3564378T3/pl unknown
- 2012-05-25 EA EA201391548A patent/EA030898B1/ru not_active IP Right Cessation
- 2012-05-25 WO PCT/EP2012/059793 patent/WO2012163811A1/en active Application Filing
- 2012-05-25 PT PT16193340T patent/PT3138916T/pt unknown
- 2012-05-25 CA CA2837393A patent/CA2837393A1/en not_active Abandoned
- 2012-05-25 CN CN201280037472.3A patent/CN103717742B/zh active Active
- 2012-05-25 MX MX2013013924A patent/MX346200B/es active IP Right Grant
- 2012-05-25 ES ES12726374.7T patent/ES2615737T3/es active Active
- 2012-05-25 US US14/122,345 patent/US9409974B2/en active Active
- 2012-05-25 SI SI201232050T patent/SI3564378T1/sl unknown
- 2012-05-25 CN CN201280037466.8A patent/CN103732750A/zh active Pending
- 2012-05-25 HU HUE16193340 patent/HUE044772T2/hu unknown
- 2012-05-25 FI FIEP19179871.9T patent/FI3564378T3/fi active
- 2012-05-25 BR BR112013030395-6A patent/BR112013030395B1/pt active IP Right Grant
- 2012-05-25 EP EP23205566.5A patent/EP4296361A3/en active Pending
- 2012-05-25 LT LTEP19179871.9T patent/LT3564378T/lt unknown
- 2012-05-25 JP JP2014511895A patent/JP2014516532A/ja active Pending
- 2012-05-25 JP JP2014511899A patent/JP5952390B2/ja active Active
- 2012-05-25 HR HRP20231749TT patent/HRP20231749T1/hr unknown
- 2012-05-25 BR BR112013030396A patent/BR112013030396A2/pt not_active IP Right Cessation
- 2012-05-25 KR KR1020137034795A patent/KR102014502B1/ko active IP Right Grant
- 2012-05-25 ME MEP-2017-26A patent/ME02600B/me unknown
- 2012-05-25 PL PL12726374T patent/PL2714911T3/pl unknown
- 2012-05-25 PT PT191798719T patent/PT3564378T/pt unknown
- 2012-05-25 CN CN201710239709.0A patent/CN107098977A/zh active Pending
- 2012-05-25 HU HUE12726374A patent/HUE030823T2/en unknown
- 2012-05-25 EP EP12726374.7A patent/EP2714911B1/en not_active Revoked
- 2012-05-25 HU HUE19179871A patent/HUE064492T2/hu unknown
- 2012-05-25 EP EP18150735.1A patent/EP3327126A1/en not_active Withdrawn
- 2012-05-25 LT LTEP16193340.3T patent/LT3138916T/lt unknown
- 2012-05-25 ES ES12724950.6T patent/ES2660468T3/es active Active
- 2012-05-25 RS RS20170051A patent/RS55605B1/sr unknown
- 2012-05-25 SI SI201231642T patent/SI3138916T1/sl unknown
- 2012-05-25 SI SI201231247T patent/SI2714910T1/en unknown
- 2012-05-25 DK DK19179871.9T patent/DK3564378T3/da active
- 2012-05-25 LT LTEP12726374.7T patent/LT2714911T/lt unknown
- 2012-05-25 US US14/122,690 patent/US9290565B2/en not_active Expired - Fee Related
- 2012-05-25 PT PT127249506T patent/PT2714910T/pt unknown
- 2012-05-25 ES ES16193340T patent/ES2743442T3/es active Active
- 2012-05-25 DK DK12726374.7T patent/DK2714911T3/en active
- 2012-05-25 EP EP19179871.9A patent/EP3564378B1/en active Active
- 2012-05-25 WO PCT/EP2012/059805 patent/WO2012163817A2/en active Application Filing
- 2012-05-25 EP EP12724950.6A patent/EP2714910B1/en active Active
- 2012-05-25 PT PT127263747T patent/PT2714911T/pt unknown
- 2012-05-25 EP EP16193340.3A patent/EP3138916B1/en not_active Revoked
- 2012-05-25 PL PL12724950T patent/PL2714910T3/pl unknown
- 2012-05-25 HU HUE12724950A patent/HUE037126T2/hu unknown
- 2012-05-25 DK DK12724950.6T patent/DK2714910T3/en active
-
2013
- 2013-11-21 IL IL229529A patent/IL229529B2/en unknown
-
2016
- 2016-02-11 US US15/041,924 patent/US9644024B2/en active Active
- 2016-06-09 JP JP2016114910A patent/JP2017012160A/ja active Pending
- 2016-06-28 US US15/194,937 patent/US10093722B2/en active Active
-
2017
- 2017-01-20 HR HRP20170094TT patent/HRP20170094T1/hr unknown
- 2017-02-03 CY CY20171100158T patent/CY1118599T1/el unknown
- 2017-02-16 SM SM201700110T patent/SMT201700110B/it unknown
- 2017-03-21 US US15/464,454 patent/US10377816B2/en active Active
-
2018
- 2018-02-15 CY CY20181100188T patent/CY1119916T1/el unknown
- 2018-02-23 HR HRP20180339TT patent/HRP20180339T1/hr unknown
-
2019
- 2019-07-17 HR HRP20191291TT patent/HRP20191291T1/hr unknown
- 2019-08-27 CY CY20191100909T patent/CY1121936T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191291T1 (hr) | Imunogeni pripravak | |
| HRP20181102T1 (hr) | Cjepiva za hsv-2 | |
| JP2017081939A5 (hr) | ||
| RU2017104529A (ru) | Композиции neisseria meningitidis и способы их применения | |
| NZ630826A (en) | Anti-egfr antibody drug conjugate formulations | |
| HRP20220717T1 (hr) | Modificirani pripravci mrna | |
| GEP20217260B (en) | Antibody neutralizing human respiratory syncytial virus | |
| HRP20190711T1 (hr) | Imunogeni pripravak | |
| WO2019143949A3 (en) | Induce and enhance immune responses using recombinant replicon systems | |
| HRP20171909T1 (hr) | Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe | |
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| WO2009072767A3 (en) | A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant | |
| JP2011250797A5 (hr) | ||
| NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
| NZ612315A (en) | Compositions for immunising against staphylococcus aureus | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| NZ601880A (en) | Compositions and methods of enhancing immune responses to eimeria | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| NZ618158A (en) | Compositions and methods for administration of vaccines against dengue virus | |
| JP2014058541A5 (hr) | ||
| WO2017156511A8 (en) | Live attenuated zika virus vaccine | |
| JP2010532766A5 (hr) | ||
| UA110024C2 (uk) | Вакцинний вектор і спосіб посилення імунної відповіді | |
| HRP20211107T1 (hr) | Mimetici obrambenih proteina domaćina, namijenjeni profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava | |
| JP2015529677A5 (hr) |